ClinicalTrials.gg
RecruitingNCT05594095Updated Oct 4, 2024

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

A Phase 2 interventional study of PIK3CA inhibitor and AKT inhibitor in Breast Neoplasm, Breast Cancer and Hormone Receptor Positive Tumor, sponsored by Fudan University. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know · 21 judgments

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies testing camrelizumab in Breast Neoplasms — 10 open to participants now, 10 under way, 2 of them phase 3. camrelizumab · Breast Neoplasms.

Planned enrollment
2nd of 21
620 · median 64
Started
2022
with 4 others
Phase 2
14 of 21
5 open now
Registered
14th of 21
by date
Lead sponsor
4 of 21
Fudan University

Among the 21 studies testing camrelizumab in Breast Neoplasms, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2022, is one of 14 in phase 2, and was the 14th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

10 of the 21 studies testing camrelizumab in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing camrelizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.

Read the detailed description

Participants in this study were hormone-receptor-positive HER2-negative patients with advanced breast cancer who had previously used CDK4/6 inhibitors. Hormone receptor positive HER2 negative was defined as ER positive (IHC ER positive percentage > 10% or PR positive (IHC PR positive percentage > 10%) and HER2 negative (IHC-/+; Or IHC++ but FISH/CISH-).

The Department of Pathology and the Key Laboratory of Breast Cancer of Fudan University Shanghai Cancer Center conducted digital pathological typing of the biopsy pathology of metastatic lesions of all participants . If the pathology of metastatic lesions could not be obtained, the digital pathological typing was performed according to the pathology of primary lesions. According to the digital pathological types of biopsy tissue and peripheral blood ctDNA, the patients were divided into four precise subtypes: SNF1, SNF2, SNF3, and SNF4. At the same time, the negative control group was randomly set by subtype stratification at 2:1. In different SNF types, patients were divided into 7 subcohorts according to the genetic PANEL results.

03

Conditions studied

  • Breast Neoplasm
  • Breast Cancer
  • Hormone Receptor Positive Tumor
  • HER2-negative Breast Cancer
  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female aged ≥18 years;
  2. HR+/- invasive breast cancer confirmed by histology (specific definition: ER >10% positive tumor cells by immunohistochemistry is defined as ER positive, PR >10% positive tumor cells is defined as PR positive, ER and/or PR positive is defined as HR positive; HER2 0-1+ or HER2 + but negative by FISH without amplification was defined as HER2 negative);
  3. Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent breast cancer;
  4. HR+/HER2- advanced breast cancer patients who had previously received CDK4/6 inhibitor therapy;
  5. At least one according to 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has not received radiotherapy);
  6. The functions of the main organs are basically normal and meet the following conditions:

    I. Blood routine examination criteria shall meet: HB ≥90 g/L (no blood transfusion within 14 days); The ANC acuity 1.5 x 109 / L; acuity 75 x 109 / L; Ii. Biochemical tests should meet the following criteria: ≤1.5× (upper limit of normal value); and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN, endogenous > 50 ml/min (Cockcroft-Gault formula);

  7. They have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study, and have recovered from the acute toxicity of previous treatment (if surgery was performed, the wound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity;
  8. score ≤2, and ≥3 months;
  9. Fertile female subjects were required to use a medically approved method during the study treatment period and for at least 3 months after the last use of the study drug;
  10. Subjects volunteered to join the study, signed , had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Radiotherapy (except for palliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment, except bisphosphonate (which can be used for bone );
  2. Uncontrolled central nervous system metastases (indicating symptomatic or symptomatic treatment with or mannitol);
  3. A history of or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6 months;
  4. Persistent grade 1 or higher adverse reactions caused by previous treatments. The exception to this is hair loss or something the researchers don't think should be ruled out. Such cases should be clearly documented in the investigator's notes;
  5. Underwent major surgery (except minor outpatient procedures, such as placement of vascular access) within 3 weeks of the first course of trial treatment;
  6. Pregnant or lactating patients; (except basal cell carcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5 years.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
620 participants (estimated)

Study arms

  • Experimental
    SNF1 1A: PIK3CA mutation

    PIK3CA inhibitors +Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.

    Drug: PIK3CA inhibitor · Drug: Aromatase Inhibitors or Fulvestrant · Drug: Goserelin

  • Experimental
    SNF1 1B: AKT pathway mutation

    AKT pathway inhibitors +Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.

    Drug: AKT inhibitor · Drug: Aromatase Inhibitors or Fulvestrant · Drug: Goserelin

  • Experimental
    SNF1 1C: without above mutation

    Everolimus 10mg po qd+Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.

    Drug: Everolimus · Drug: Aromatase Inhibitors or Fulvestrant · Drug: Goserelin

  • Experimental
    SNF2 2A

    Treatment of physician' choice+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib 15mg po qd for 4 weeks as a cycle

    Drug: Carrelizumab · Drug: Famitinib · Drug: TPC

  • Experimental
    SNF3 3A: Stratification of BRCA/PALB2 expression

    Fluzoparib SHR3162 100mg po qd+Dalpiciclib 125mg po qd for 4 weeks as a cycle

    Drug: Fluzoparib · Drug: Dalpiciclib

  • Experimental
    SNF4 4A: HER2 low

    SHR-A1811

    Drug: SHR-A1811

  • Active comparator
    The control arm

    Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)

    Drug: TPC

  • Experimental
    SNF3 3B:

    Fluzoparib SHR3162 100 mg qd+Treatment of physician' choice

    Drug: Fluzoparib · Drug: TPC

  • Experimental
    SNF4 4B:

    Apatinib 250mg qd+Treatment of physician' choice

    Drug: TPC · Drug: Apatinib

  • Experimental
    SNF1 1D: without above mutation

    Everolimus 10mg po qd+Treatment of physician' choice

    Drug: Everolimus · Drug: TPC

  • Experimental
    SNF1 1E: HER2 LOW

    Everolimus 10mg po qd+SHR-A1811

    Drug: SHR-A1811 · Drug: Everolimus

  • Experimental
    SNF1 1F: HER2 zero

    Everolimus 10mg po qd+SHR-A1921

    Drug: Everolimus · Drug: SHR-A1921

  • Experimental
    SNF2 2B: HER2 zero

    SHR-A1921+Pd-1 mab (Carrelizumab 200mg Q2W)+bevacizumab 7.5mg po ivgt t for 3 weeks as a cycle

    Drug: Carrelizumab · Drug: SHR-A1921 · Drug: bevacizumab

  • Experimental
    SNF2 2C:

    HER3 -ADC+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle

    Drug: Carrelizumab · Drug: Famitinib · Drug: SHR-A2009

  • Experimental
    SNF2 2D:

    Nectin4-ADC+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle

    Drug: Carrelizumab · Drug: Famitinib · Drug: SHR-A2102

  • Experimental
    SNF2 2E: HER2 low

    SHR-A1811+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle

    Drug: Carrelizumab · Drug: Famitinib · Drug: SHR-A1811

  • Experimental
    SNF3 3C:

    CDK4i(SHR-6209 PR2D+PARP1i(SHR-1167 PR2D)

    Drug: SHR-1167 · Drug: SHR-6209

  • Experimental
    SNF3 3D:

    PARP1i(SHR-1167 PR2D)+Famitinib 5mg po qd for 4 weeks as a cycle

    Drug: Famitinib · Drug: SHR-1167

  • Experimental
    SNF3 3E: HER2 low

    PARP1i(SHR-1167 PR2D)+SHR-A1811 for 3 weeks as a cycle

    Drug: SHR-A1811 · Drug: SHR-1167

  • Experimental
    SNF3 3F: HER2 zero

    PARP1i(SHR-1167 PR2D)+SHR-A1921 for 3 weeks as a cycle

    Drug: SHR-A1921 · Drug: SHR-1167

  • Experimental
    SNF4 4C

    Famitinib 20mg po qd

    Drug: Famitinib

  • Experimental
    SNF4 4D

    Sorafenib 0.4g bid

    Drug: Sorafenib

  • Experimental
    SNF4 4E

    Apatinib 500mg qd

    Drug: Apatinib

  • Experimental
    SNF4 4F: HER2 low

    Famitinib+SHR-A1811 for 3 weeks as a cycle

    Drug: Famitinib · Drug: SHR-A1811

  • Experimental
    SNF4 4G

    Famitinib+HER3-ADC for 3 weeks as a cycle

    Drug: Famitinib · Drug: SHR-A2009

  • Experimental
    SNF4 4H

    Famitinib+Nectin4-ADC for 3 weeks as a cycle

    Drug: Famitinib · Drug: SHR-A2102

Interventions

This study also gives FulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1)

    Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 3 years)

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    the percentage of subjects with CR+PR+SD and last more than 24 weeks in all of the subjects

    Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 3 years

  2. Progression Free Survival (PFS)

    time to progressive disease (according to RECIST1.1)

    Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 3 years)]

  3. Overall Survival (OS)

    time to death due to any cause

    Time frame: Randomization to death from any cause, through the end of study (approximately 3 years)

  4. CTCAE scale (V5.0)

    To evaluate the rate of adverse effects of patient by the standard CTCAE scale (V5.0)

    Time frame: up to One Year during follow-up

  5. Exploration of translational research markers

    The collected subjects' tumor tissues, paracancerous tissues, blood, and fecal samples will be used for discovering exploratory biomarkers. The relationships between discovered biomarkers and subjects' disease status and treatment responses will also be investigated.

    Time frame: up to One Year during follow-up

07

Study locations

1 of 1 sites recruiting
  • Breast cancer institute of Fudan University Cancer Hospital
    Shanghai, Shanghai 200032, China
    Recruiting
    • Zhi-Ming Shao, MD · Contactzhimingshao@yahoo.com · 86-21-641755901105
    • Lei Fan, MD · Contactcmchen@medmail.com.cn · 86-21-641755901105
    • Zhi-Ming Shao, MD · Principal investigator
    • Lei Fan, MD · Sub investigator
    • Wenjuan Zhang, MD · Sub investigator
    • Ying Zhou · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2025, 35 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 35 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Oct 26, 2022
StartActual
Dec 30, 2022
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2026
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05594095
Lead sponsor
Fudan University
Collaborators
Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Responsible party
Zhimin Shao (Professor, Fudan University) — Principal investigator
First posted
Oct 26, 2022
Start date
Dec 30, 2022
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 4, 2024

Study contacts

Zhimin Shao, M.D
Contact
zhimingshao@yahoo.com
+86-021-64175590 ext. 88807

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Famitinib · Fluzoparib · Dalpiciclib · Trastuzumab rezetecan · Everolimus · Goserelin · Sorafenib · Apatinib · Tizetatug rezetecan · Notiretatug rezetecan · Ruzaltatug rezetecan

Start the discussion